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Abstract: Inflammatory bowel disease (IBD) characterizes chronic gastrointestinal inflammation man-
ifested by abdominal pain, diarrhea, malabsorbtion and bleeding, of which two phenotypes, Crohn’s
disease (CD) and ulcerative colitis (UC) have been described [1-3]. It affects about 1.4 million people
in the USA and 2.2 million people in Europe [4, 5]. The nuclear receptor farnesoid X receptor senses
intracellular bile acid levels. In response to elevated levels of intracellular bile acids, activated FXR
induces gene expression of bile acid efflux transporters whereas the expression of bile acid uptake trans-
porters are down regulated, thus protecting against bile acid toxicity in the liver and intestine. FXR
regulates several genes that can protect against intestinal inflammation and bacterial overgrowth. FXR-
deficient mice have increased ileal concentrations of gut bacteria and exhibit defects in the integrity of
the intestinal epithelial barrier. Furthermore, in rodent models of colitis and in CD patients, it has
been reported that reduced expression of FXR is associated with colon inflammation [6]. The fact that
FXR thus appears to play a role in the protection of the integrity of the intestinal epithelial barrier and
its inverse correlation with the level of intestinal inflammation suggest a potential connection between
FXR and the molecular pathogenesis of IBD. In the first chapter of this thesis, we have investigated five
FXR single nucleotide polymorphisms - two common SNPs and three rare variants - which have been
previously studied in the context of human disease, in a well sized IBD vs non-IBD cohort, and report
that two of these genetic variants are associated with IBD. NF-￿B activity is upregulated in patients
with IBD, characterized by high circulatory levels of cytokines especially tumor necrosis factor (TNF).
Low plasma concentration of high density lipoprotein (HDL) cholesterol is a marker and considered as a
risk factor for coronary heart disease, diabetes mellitus, and several cancers including colorectal cancers
[7-9]. The intestine plays a crucial role in HDL metabolism. In addition, the classical anti-atherogenic
function of HDL, the mediation of reverse transport of excess cholesterol from macrophages of the arterial
wall to the liver is completed by biliary excretion of cholesterol into the intestine. Intestinal dysfunction
and inflammation leads to decrease in serum levels of HDL cholesterol and ApoA1 [10-13]. Consistent
with this, clinical studies show significantly lower HDL-cholesterol levels in patients with active IBD [14].
Traditionally, the low HDL cholesterol in IBD patients is interpreted as the consequence of IBD. The
association of low HDL-cholesterol with IBD together with the many anti-inflammatory properties of
HDL however raises the question of whether HDL and its protein and lipid components have any causal
impact on intestinal inflammation in IBD patients. In the second chapter of the thesis, we approached
this question and investigated the effect of HDL and ApoA1 on intestinal inflammation both in vitro and
in vivo. Autophagy, a catabolic process involving intracellular degradation of organelles and proteins,
has been shown to be compromised in many human diseases including IBD. Autophagy malfunction has
been attributed to defective clearance of pathogens and dysfunction of paneth and goblet cells, which
are relevant for pathogenesis of IBD. In the third chapter of the thesis, we put forward autophagy as a
mechanism by which HDL suppress intestinal inflammation.
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SUMMARY 
Inflammatory bowel disease (IBD) characterizes chronic gastrointestinal inflammation 
manifested by abdominal pain, diarrhea, malabsorbtion and bleeding, of which two 
phenotypes, Crohn’s disease (CD) and ulcerative colitis (UC) have been described [1-3]. It 
affects about 1.4 million people in the USA and 2.2 million people in Europe [4, 5].  
The nuclear receptor farnesoid X receptor senses intracellular bile acid levels. In response 
to elevated levels of intracellular bile acids, activated FXR induces gene expression of bile 
acid efflux transporters whereas the expression of bile acid uptake transporters are down 
regulated, thus protecting against bile acid toxicity in the liver and intestine. FXR regulates 
several genes that can protect against intestinal inflammation and bacterial overgrowth. 
FXR-deficient mice have increased ileal concentrations of gut bacteria and exhibit defects 
in the integrity of the intestinal epithelial barrier. Furthermore, in rodent models of colitis 
and in CD patients, it has been reported that reduced expression of FXR is associated with 
colon inflammation [6]. The fact that FXR thus appears to play a role in the protection of 
the integrity of the intestinal epithelial barrier and its inverse correlation with the level of 
intestinal inflammation suggest a potential connection between FXR and the molecular 
pathogenesis of IBD.  
In the first chapter of this thesis, we have investigated five FXR single nucleotide 
polymorphisms - two common SNPs and three rare variants - which have been previously 
studied in the context of human disease, in a well sized IBD vs  non-IBD cohort, and report 
that two of these genetic variants are associated with IBD.  
NF-κB activity is upregulated in patients with IBD, characterized by high circulatory levels 
of cytokines especially tumor necrosis factor (TNF).  Low plasma concentration of high 
density lipoprotein (HDL) cholesterol is a marker and considered as a risk factor for 
coronary heart disease, diabetes mellitus, and several cancers including colorectal cancers 
[7-9].    
The intestine plays a crucial role in HDL metabolism. In addition, the classical anti-
atherogenic function of HDL, the mediation of reverse transport of excess cholesterol from 
macrophages of the arterial wall to the liver is completed by biliary excretion of cholesterol 
into the intestine. Intestinal dysfunction and inflammation leads to decrease in serum levels 
of HDL cholesterol and ApoA1 [10-13]. Consistent with this, clinical studies show 
significantly lower HDL-cholesterol levels in patients with active IBD [14]. Traditionally, 
the low HDL cholesterol in IBD patients is interpreted as the consequence of IBD. The 
association of low HDL-cholesterol with IBD together with the many anti-inflammatory 
properties of HDL however raises the question of whether HDL and its protein and lipid 
components have any causal impact on intestinal inflammation in IBD patients.  
In the second chapter of the thesis, we approached this question and investigated the effect 
of HDL and ApoA1 on intestinal inflammation both in vitro and in vivo.  
Autophagy, a catabolic process involving intracellular degradation of organelles and 
proteins, has been shown to be compromised in many human diseases including IBD. 
Autophagy malfunction has been attributed to defective clearance of pathogens and 
dysfunction of paneth and goblet cells, which are relevant for pathogenesis of IBD. In the 
third chapter of the thesis, we put forward autophagy as a mechanism by which HDL 
suppress intestinal inflammation. 
  
ZUSAMMENFASSUNG 
Chronisch entzündliche Darmerkrankungen (IBD), bestehend aus Morbus Crohn (CD) und 
Colitis ulcerosa, (UC) charakterisieren chronisch gastrointestinale Entzündungen, welche 
durch Bauchschmerzen, Durchfall, Malabsorption und Blutungen manifestiert werden [1-
3]. Es betrifft etwa 2,2 Millionen Menschen in Europa und 1,4 Millionen Menschen in den 
USA [4, 5].  
Der Kernrezeptor Farnesoid X-Rezeptor (FXR) stellt intrazelluläre Gallensäure fest. In 
Reaktion auf erhöhten intrazellulären Gallensäuren, induzieren aktivierte FXR 
Genexpression von Gallensäure Effluxtransporter, wohingegen die Expression von 
Gallensäure-Aufnahme Transportern herunterreguliert sind, und somit Schutz gegen 
Gallensäure Toxizität in der Leber und Darm bieten. FXR regelt mehrere Gene, die gegen 
Darmentzündungen und bakteriellen Überwucherung schützen können. Fxr-defiziente 
Mäuse haben erhöhte ileale Konzentrationen von Darmbakterien und weisen Defekte in 
der Integrität und Funktion des intestinalen Epithelbarriere auf. Weiterhin wurde berichtet, 
dass eine reduzierte Expression von FXR mit Darmentzündung in Nagermodellen von 
Colitis und im CD-Patienten assoziiert wird [6]. Die Tatsache, dass FXR somit eine Rolle 
beim Schutz der Integrität der intestinalen Epithelbarriere und seine inverse Korrelation 
mit dem Niveau der intestinalen Entzündungen spielt, scheint auf eine potentielle 
Verbindung zwischen FXR und der molekularen Pathogenese der IBD zu deuten. Zwei 
gemeinsame SNPs und drei seltene Varianten wurden in einem IBD vs nicht-IBD-Kohorte 
untersucht. 
Im ersten Kapitel dieser Arbeit haben wir fünf FXR Single Nucleotide Polymorphismen 
untersucht und berichten, dass zwei dieser genetischen Varianten mit IBD verbunden sind. 
NF-kB-Aktivität wird bei Patienten mit IBD durch hohe Konzentration von insbesondere 
Zytokine Tumornekrosefaktor (TNF) hochreguliert. Eine niedrige Plasmakonzentration 
von Lipoprotein mit hoher Dichte (HDL) ist ein Risikofaktor für koronare Herzkrankheit, 
Diabetes mellitus und einige Krebsarten wie Darmkrebs [7-9,10-13].  
Der Darm spielt eine wichtige Rolle in HDL Stoffwechsel. In der klassischen 
antiatherogenen Funktion der HDL, wird überschüssiger Cholesterin aus Makrophagen der 
Arterienwand in die Leber durch HDL zurück transportiert und endet mit biliären 
Ausscheidung von Cholesterin in den Darm.  
Disfunktionen und Entzündungen im Darm führen zu niedrigen Serumspiegel von HDL-
Cholesterin und ApoA1 [14-17,18-21]. Im Einklang mit dieser zeigen klinische Studien 
deutlich niedrigere HDL-Cholesterinspiegel bei Patienten mit aktiver IBD [22]. 
Traditionell wird das niedrige HDL-Cholesterin bei IBD-Patienten als Folge der 
chronischen Entzündung interpretiert. Der Verband der niedrigen HDL-Cholesterin mit 
IBD wirft zusammen mit den vielen anti-inflammatorische Eigenschaften von HDL 
allerdings die Frage auf, ob HDL und sein Protein/Lipid-Komponente einen Einfluss auf 
die Darmentzündung bei IBD-Patienten haben. Im zweiten Kapitel der Dissertation 
näherten wir uns dieser Frage und untersuchten die Wirkung von HDL und Apo-A1 auf 
Darmentzündung, sowohl in vitro als auch in vivo.  
Autophagie ist ein intrazellulärer Abbauprozess, das in vielen menschlichen Krankheiten 
einschließlich IBD beeinträchtigt werden. Autophagy Fehlfunktion führt zu mangelhafter 
Clearance von Pathogenen und Dysfunktion der Paneth- und Becherzellen, die relevant für 
die Pathogenese der IBD sind. Im dritten Kapitel der Arbeit schlagen wir Autophagie als 
eine mögliche Mechanismus vor, durch der HDL die Darmentzündung unterdrückt. 
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1 INTRODUCTION 
1.1 Physiology of intestine 
The small intestine and colon primarily form the gut whose primary function is digestion 
and absorption of nutrients. The small intestine is structurally divided into the duodenum, 
jejunum and the ileum. Epithelial protrusions called villi increases the surface area of the 
small intestine. The intestinal mucosa is constantly exposed to dietary antigen and 
commensal bacteria. The gut therefore has to keep a state of balance on one hand 
preventing overwhelming immune responses whereas at the same time maintaining 
mucosal integrity.  
A monolayer of intestinal epithelium build a physical barrier to foreign antigen and 
influence immune cell proliferation and differentiation by producing a myriad of signaling 
molecules. The intestinal epithelial monolayer include  columnar epithelial cells with 
absorptive function, goblet cells that secrete mucous, Paneth cells that secrete 
antimicrobial defensins as well as lysozymes and hormone secreting enteroendocrine cells, 
forming a physiological barrier against commensal and invasive pathogens which is 
equally important as its role in absorption of water, salts and nutrients (Fig 1).  Columnar 
epithelial cells also known as enterocytes are polarized with an apical brush border that is 
in contact with the luminal contents and a basolateral membrane adjacent to stroma. Each 
enterocyte is connected by intercellular junctions (Tight junction, adheren junction and 
desmosomes) which contribute to the barrier function. A coat of glycoproteins (mucin) 
occupies surface receptors of enterocytes, limiting the attachment of microbes from the 
lumen. Beneath the mucin layer lies the glycocalyx layer with adsorbed enzymes on the 
negatively charged microvilli, responsible for digestion. In addition, lymphoid aggregates 
called Peyers patches are distributed in the epithelia. These are overlaid by Microfold (M) 
cells that deliver antigen to lymphoid follicles of Peyer’s patches. The lamina propria with 
antigen presenting cells (APCs) such as dendritic cells and macrophages lies beneath the 
epithelia separated by a basal membrane [15]. The intestinal epithelium is renewed every 
4-5 days by proliferative crypts of Lieberkühn which contain intestinal stem cells. 
Disruption of the barrier can lead to an uncontrolled inflammation triggered by microbes as 
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seen in inflammatory bowel disease (IBD) [16, 17]. The epithelia also act as antigen 
presenting cells, capable of internalizing (via endocytosis or pinocytosis), processing and 
presenting foreign antigen to dendritic cells in the lamina propria. 
Figure 1: Intestinal Epithelium  
(adapted from [18]) 
Intestinal epithelium is involved in immune cell regulation and antigen processing despite building 
a physical barrier against commensal bacteria and foreign antigen. The epithelia is folded into 
crypts and villous protrusions. Intestinal epithelial cell differentiation takes place in the crypt. Four 
types of intestinal epithelial cells are derived from pluripotent stem cells of the crypt. The goblet, 
enteroendocrine and absorptive cells, which migrate to the tip of villus where as the fourth lineage, 
paneth cells remains within the crypt [18]. 
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1.2 Immune functions of intestinal mucosa 
The intestine forms the largest part of immune system with a surface area of 400 m2 being 
exposed to enormous antigenic burden of dietary or commensal origin. Atleast 1013 to 1014 
commensal bacteria cohabit the gastrointestinal tracts carrying out essential functions such 
as digestion, nutrient supply (especially vitamin B and folates) and fine tuning mucosal 
immune system [19, 20] . Despite the extreme antigenic burden, the epithelia maintain a 
passive mucosal inflammatory response which is achieved by limiting initial immune 
responses  via secretion of anti-inflammatory cytokines and recruiting immune regulatory 
cells. The gut associated lymphoid tissue, lamina propria cells and enterocytes actively 
play a role in maintaining passive unresponsiveness to antigens. The epithelium produces 
antimicrobial proteins such as lysozymes, defensins, cathelicidins, RNases and C-type 
lectins to resist microbial invasion of the tissue. The most abundant antibody isotype 
produced in the body, secretory Immunoglobulin A (IgA), is transcytosed to apical and 
basolateral surface where they bind to polymeric Ig receptor providing mucosal protection 
and contribute to barrier function of the epithelium. The epithelial monolayer forms a thin 
physical barrier preventing penetration of pathogens from the intestinal lumen [21, 22] . 
Intraepithelial lymphocytes which express αβ (with CD4 or CD8 coreceptors) or γδ (with 
CD8 coreceptor) T-cell receptors, monitor stressed or damaged intestinal epithelial cells 
[23, 24].  The intestinal epithelia express immune receptors such as Toll like receptors 
(TLR), Nod like receptor (NLR) and C-type lectin receptor (CLR) which recognize and 
bind pathogen associate molecular pattern (PAMP) expressed on microbial surface and 
upregulate  antimicrobial factors as well as secretion of cytokines and chemokines via 
activation of NF-κB pathway [25, 26]. Mutations in nucleotide oligomerization domain-2 
(NOD2/CARD15) also known as IBD1 which recognizes muramyl di peptide (MDP), is 
strongly linked to IBD with a strong predisposition to CD [27]. Variants in TLR4 gene 
which recognizes LPS has also been implicated [28]. The gut associated lymphoid tissue 
(GALT) is scattered throughout the epithelia, lamina propria Peyer’s patches and 
mesenteric lymph nodes (MLN) and is rich in B and T lymphocytes, [29]. The Peyer’s 
patches are lymphoid aggregates in the submucosa, consisting of collection of B cell 
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follicles and T cell areas. The MLNs which are the largest lymph nodes in the body lies 
between layers of mesentry, stretching across jejunum and ileum. 
 
Figure 2:  Intestine as an immune organ  
(adapted from [30]) 
Intestinal epithelial cells sense PAMPs through TLR and NLR pattern recognition receptors, 
which activates transcription factor NF-κB via MyD88. NLR family members NOD1 and 
NOD2 senses peptidoglycans (PGN), a component of bacterial cell wall inducing recruitment of 
RICK and adapter protein CARD9, further activating NF-κB and MAP kinases which induces 
the expression of proinflammatory cytokines. NOD like receptor protein 3 (Nlrp3) senses 
patterns of microbial and non microbial origin and forms a multiprotein complex with apoptosis 
associated speck like protein (ASC) and CARD domain of caspase-1 called the inflammasome 
which plays a crucial role in the inflammatory process by activating caspase-1 and mediates 
production of pro-inflammatory cytokines IL-1β and IL-18 [30]. 
  
INTRODUCTION 
5 
 
1.3 Pathogenesis and genetics of inflammatory bowel disease (IBD) 
Inflammatory bowel diseases (IBD) characterizes a chronic disease manifested by 
recurrent inflammation of intestinal mucosa that results from aberrant regulation of the 
mucosal immune system resulting in excessive production of inflammatory cytokines, in 
genetically susceptible individuals. The etiology of IBD involves a complex interaction of 
genetic, environmental, and immunomodulatory factors. Two major forms of chronic 
mucosal inflammation have been defined. In Crohn’s disease (CD), any part of the 
gastrointestinal tract may be affected, although the most frequent site of inflammation is 
the terminal ileum, whereas in ulcerative colitis (UC) inflammation typically affects the 
mucosa of colon (Fig 3) [31].  
In IBD, both UC and CD are characterized by a weakened gut barrier, with increased 
infiltration of gut bacteria. Recruitment of neutrophils and formation of crypt abscess 
following antigen infiltration is typical for UC, where as in CD, macrophages are recruited 
with formation of granulomas [32, 33]. Tissue damage occurs mainly due to heavy 
infiltration of CD4+ T lymphocytes which are recruited from blood stream via enhanced 
production of chemoattractants such as CCL25 which promotes migration of CC 
chemokine receptor 9 (CCR9)- expressing T-cells to the intestinal mucosa [34]. Cytokines 
such as IL-15 and IL-21 which trigger anti-apoptotic programs in CD4+ T cells are 
produced in excess in IBD which may contribute to diminished susceptibility of IBD 
associated T-lymphocytes to apoptosis, leading to their accumulation in the gut wall, 
resulting in chronic inflammation [35-37]. The pathogenesis of CD exhibit a predominant 
Th1 mediated response with increased levels of interferon-γ and TNF as well as Th17 
cytokine IL17, UC by contrast is characterized by an exaggerated Th2 response with 
increased production of IL13 and IL17 [38, 39]. Polymorphisms of multiple genes in the 
IL23 pathway that is central to the function of Th17 cells have been associated with CD 
and UC [40-42]. For CD pathogenesis, a strong genetic component has been suggested by 
the concordance of 63.6% in monozygotic twins, but only of 3.6% in dizygotic twins. The 
concordance of monozygotic twins is lower (6%) in UC, indicating that genetic 
susceptibility may play a somewhat smaller role in this disease [43]. Prior studies have 
revealed more than 100 genes that are potentially associated with IBD [44, 45]. The region 
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on chromosome 16q11-12 named IBD1 was identified in 1996, and the fine mapping of 
this region led to the identification of the NOD2 (nucleotide-binding oligomerization 
domain 2)/CARD15 (caspase activation recruitment domain 15) gene [46, 47] a member of 
a family of pattern recognition receptors (PRRs) that recognizes microbial components and 
modifies inflammatory responses to bacterial triggers, such as lipopolysaccharides (LPS), 
through the activation of NF-κB [48, 49]. Furthermore, genes that are essential in 
immunological cell-cell interactions and signalling, such as the tumour necrosis factor 
receptor 1 (TNFR1) [50], the interleukin-23 receptor (IL23R) [51], and other genes that are 
involved in immune response to bacteria, such as the toll-like receptor 4 (TLR4) [52, 53], 
have been proposed to be associated with IBD. In addition, regulatory genes, such as the 
protein tyrosine phosphatase N2 (PTPN2) [54, 55] and the anti-inflammatory nuclear 
receptor peroxisome proliferator-activated receptor-γ (PPARγ) [56], as well as genes 
encoding membrane transporters multidrug resistance gene 1 (MDR1) [57-59] and the 
organic cation transporter 1/2 (OCTN1/2) [57, 60] have been associated with the risk of 
chronic mucosal inflammation. 
 
(adapted from http://iconsinmedicine.wordpress.com/2011/02/28/inflammatory-bowel-disease) 
In UC, inflammation is confined to the colon and the inner lining of the intestinal wall is affected 
whereas in CD, the ileum is frequently inflamed. Both are characterized by diarrhea, weight loss, 
rectal bleeding, abdominal cramps, fever and pain. 
  
Figure 3: Phenotypes of inflammatory bowel disease 
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1.4 NF-κB – a key regulator of intestinal inflammation 
The transcription factor NF-κB plays a crucial role in initiating inflammatory cascades in 
response to extracellular stimuli such as microbial products, cytokines, reactive oxygen 
species, hypoxia and endoplasmic reticulum stress [61]. The intestinal tract is prone to 
inflammatory insult due to presence of endogenous microflora as well as food derived 
antigens. Activation of NF-κB is pivotal in preserving intestinal immune homeostasis. Five 
proteins, Rel A (P65), Rel B, c-Rel, P105 and P100 constitute the NF-κB family of 
transcription factors in mammals. These proteins form homo- or heterodimers to bind to 
κB sites in the promoter region of target genes. Rel A, Rel B and c-Rel contain a 
transactivation domain capable of activating κB containing promoters, whereas P105 and 
P100 have an inhibitory domain consisting of ankyrin repeats which has to be cleaved to 
active P50 and P52 respectively [62]. NF-κB dimers are retained inactive in the cytoplasm 
bound to an inhibitory protein IκB (inhibitor of κB). IKK (IκB kinase) complex which 
consists of two catalytically active kinases IKKα and IKKβ and a regulatory subunit IKKγ 
(NEMO) is activated by a wide range of stress signals such as TNF or LPS. IKK 
phosphorylates IκB at its serine residues and marks for K48 ubiquitination and degradation 
by proteasome, the released NF-κB dimer translocates to the nucleus and transcribes genes 
involved in inflammation such as TNF, IL-1β, IL-6, IL-8, ICAM, iNOS, (Fig 4) [63-65]. 
Two types of NF-κB signaling pathways have been described. The canonical pathway is 
induced by activation of TNFR1 (tumour necrosis factor receptor 1) by pro-inflammatory 
signals such as cytokines, PAMPs and DAMPs (danger associated molecular patterns), 
leading to binding of TRADD (TNF receptor associated death domain) which recruits 
TRAF2. TRAF2 associates with receptor interacting protein kinase1 (RIPK1) and binds 
inhibitor of apoptosis (cIAPs), to activate IKK. IκB is phosphorylated by IKKβ and 
NEMO in the canonical pathway. In contrast, the non-canonical pathway is induced by 
cytokines such as CD40L and lymphotoxin-β (LT-β) leading to activation of NF-κB 
inducing kinase (NIK) which activates IKKα that further phosphorylates and processes 
P100 associated with RelB to generate the transcriptionally active P52-Rel B complex [64, 
66, 67]. This pathway is important during B and T cell development. Post translational 
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modifications (phosphorylation, acetylation and prolyl isomerization) of NF-κB subunits 
have been shown to modulate their transcriptional activity [68] . 
 
NF-κB is activated through IKK mediated phosphorylation followed by proteasomal 
degradation of inhibitory protein IκB, releasing NF-κB subunits, which translocate to the 
nucleus and induce target gene expression. In the canonical pathway, binding of ligands such as 
TNF to its receptor recruits adaptors TRAF2 and TRADD to the cytoplasmic domain of the 
receptor, which further interact with RIPK1 and cIAP activating the IKK complex. 
  
Figure 4: The canonical pathway of NF-κB activation 
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1.5 TNF – the major cytokine initiating intestinal inflammation 
TNF is a 26 kDa protein, which is secreted and expressed on the plasma membrane of 
activated macrophages and T –lymphocytes and is cleaved by matrix metalloproteinases to 
a soluble 17 kDa protein. Both forms of TNF exert their effect by binding as a trimer to 
cell membrane receptors TNFR-1 (55 kDa) or a TNFR-2 (75 kDa) [69-71]. Clathrin coated 
pits  internalize the ligand receptor complex which fuse with lysosomes where TNF is 
degraded. Binding of TNF to TNFR-2 is not sufficient to attain cytotoxicity whereas 
binding to TNF-R1 mediates cell toxicity [72]. TNF exerts its effect by activating a 
number of proteins: transcription factors such as AP-1, NF-κB, protein kinases (erk-1, erk-
2 and MAP2), phospholipases (PLA2, PLC, PLD and sphingomyelinase), mitochondrial 
proteins (manganese superoxide dismutase) and caspases [70, 73-75]. The biological 
functions of TNF include immunostimulation, resistance to infectious agents, resistance to 
tumours, sleep regulation and embryonic development [75-77]. Many cell types including 
macrophages, monocytes, lymphocytes, mast cells, leukocytes, astrocytes, microglial cells, 
keratinocytes, tumor cells and intestinal Paneth cells produce TNF. During inflammation, 
TNF is secreted by T helper 1 cells and act synergistically with IFNγ and IL17 to 
propagate inflammation. In contrast TNF downregulates T-cells and releases nitric oxide 
and prostaglandin from macrophages to regulate chronic TNF secretion [78-81]. mRNA 
expression of TNF is regulated at the level of mRNA stability and translation [82-84]. The 
AU-rich element (ARE) at the 3’ un-translated region (UTR) of TNF confers mRNA 
instability and repression of TNF in unstimulated cells. Interaction between RNA binding 
protein Tris tetra proline (TTP) with 3’-UTR ARE of TNF modulates recruitment of 
exosomes for degradation of TNF, thus increasing the rate of TNF mRNA turnover under 
basal conditions [85-87].  
TNF is a major mediator in the pathophysiology of inflammation especially in IBD. In 
animal models of colitis, TNF expression is significantly increased in the inflamed 
intestine and inhibition of TNF appears to reduce the disease severity [88-91]. Currenly 
three TNF blockers are in clinical use to treat IBD. Infliximab, a chimeric mouse human 
IgG1 monoclonal antibody to TNF, is able to neutralize circulating and membrane bound 
TNF as well as induce apoptosis of  T cells and monocytes [92-99]. Adalimumab is a 
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recombinant human monoclonal antibody which block TNF interaction with its receptors 
and induce T cell and monocyte apoptosis like infliximab [100]. Certolizumab pegol is a 
pegylated monoclonal antibody which bind and neutralizes membrane associated and 
soluble human TNF [101]. Inhibitors of TNF have been shown to be relieve symptoms in 
chronic inflammatory diseases such as IBD, psoriasis, ankylosing spondylitis and psoriatic 
arthritis [102].  
 
1.6 Nuclear receptor FXR and intestinal inflammation [103] 
Nuclear receptors represent a large family of transcription factors that regulae numerous 
processes, including reproduction, development, and a wide range of metabolic pathways 
[104]. The ligand-dependent activation function at the carboxy-terminus of most nuclear 
receptors allows them to sense metabolic changes within cells, and in response carry out 
rapid transcriptional changes [105-107].  
The farnesoid X receptor (FXR); gene symbol NR1H4 (nuclear receptor subfamily 1, 
group H, member 4) is a nuclear receptor that functions as the main sensor of intracellular 
bile acid levels [108-110]. The human NR1H4 gene, composed of 11 exons and 10 introns 
is located on chromosome 12 [111]. The translation initiation codon of the NR1H4 gene 
lies at the 3′ end of exon 3, whereas exons 1 and 2, together with the 5′ region of exon 3, 
contain the 5′ non-translated region (5’-UTR).  
Multiple FXR isoforms can be generated via alternative promoter usage and alternative 
splicing, and these isoforms may have differential transactivation abilities on specific 
target promoters [112]. FXR typically acts by binding to FXR response elements within the 
target promoters as heterodimers with another member of the nuclear receptor family, 
retinoid X receptor-α (RXRα) [113]. In response to elevated levels of intracellular bile 
acids, activated FXR is well known to induce protective gene expression circuits against 
bile acid toxicity in the liver and intestine [114]. Expression of bile acid efflux systems in 
ileocytes (organic solute transporter α/β; OSTα/β) [115, 116] and hepatocytes (bile salt 
export pump; BSEP) [117-119] is upregulated by bile acid-activated FXR, while the 
expression of the respective bile acid uptake systems apical sodium-dependent bile acid 
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transporter (ASBT) [120] and Na+-taurocholate co-transporting polypeptide (NTCP) [121, 
122] is suppressed by it. Transcription of the three major genes coding for bile acid 
synthesizing enzymes, namely cholesterol-7α-hydroxylase (CYP7A1), sterol-12α-
hydroxylase (CYB8B1), and sterol-27-hydroxylase (CYP27A1) are repressed by FXR 
[123, 124]. Thus, elevated levels of bile acids can suppress their own de novo production 
through a negative feedback loop involving FXR (Fig 5). In addition, FXR regulates 
several genes that can protect against intestinal inflammation and bacterial overgrowth [6, 
125, 126]. Fxr-deficient mice have increased ileal concentrations of gut bacteria and 
exhibit defects in the integrity of the intestinal epithelial barrier. In agreement with this, the 
products of a number of genes that are regulated by Fxr in the ileum, including angiogenin 
(Ang1), inducible nitric oxide synthase (iNos), and interleukin-18 (Il-18), are known to 
have antimicrobial actions [126]. Furthermore, it has been reported that reduced expression 
of FXR is associated with colon inflammation in rodent models of colitis and in CD 
patients [6].  
Recently, FXR activation was shown to decrease NF-κB-mediated immune responses and 
intestinal permeability in mouse models of colitis [127]. It was subsequently shown that 
intestinal inflammation reduces FXR activation as well as the expression of FXR target 
genes such as intestinal bile acid-binding protein (IBABP) and fibroblast growth factor 
15/19 (FGF15/19) [128]. In agreement with this, it has been proposed that FXR may 
contribute to the resistance of both human and mouse gastric epithelial cells against 
inflammation-induced injury [129].  
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CDCA, the major component of bile acids, is a potent ligand of FXR, inducing heterodimerization 
of FXR with RXRα leading to induction of bile acid efflux transporters OSTα/β and BSEP. Also a 
repressor protein SHP is induced which inhibits the expression of CYP7A1 thus suppressing bile 
acid synthesis. Also bile acid uptake transporters such as NTCP and ASBT is repressed via SHP 
thus protecting hepatocytes against bile acid overload and toxicity. 
 
1.7 High density lipoprotein 
High density lipoproteins are a class of spheroidal plasma lipoproteins with a density of 
1.063 to 1.21 g/mL comprising of apolipoproteins (ApoA1 ApoAII and ApoCIII), 
phospholipids and a core of cholesteryl esters [130]. They are the smallest and densest of 
lipoprotein particles with highest proportion of protein to cholesterol. Five subfractions of 
HDL have been defined, varying in size (8-11 nm in diameter) and density. HDL has been 
shown to promote cholesterol efflux from artery walls and peripheral tissues, transporting 
it back to the liver in a process called reverse cholesterol transport (RCT). Low levels of 
HDL cholesterol (HDL-C) in plasma is inversely related to the risk of cardiovascular 
Figure 5:  Regulation of bile acid homeostasis 
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disease [131, 132]. An increment of 1mg/dL in HDL-C has been shown to reduce mortality 
from cardiovascular disease by 3-4% [133].  
ApoA1, the major protein of HDL is secreted by liver and intestine which form nascent 
HDL after acquiring phospholipids and free cholesterol via interaction with the ATP-
binding cassette A1 (ABCA1) transporter [134]. Mature HDL is generated by Lecithin 
cholesterol acyltransferase (LCAT) which esterifies free cholesterol to cholesteryl esters. 
This process increases the cholesterol uptake capacity of HDL and enable it to accept 
cholesterol via interaction with ATP-binding cassette G1 (ABCG1) receptors expressed by 
macrophages [135, 136]. Liver X receptor (LXR) regulates the expression of cellular 
ABCA1 and ABCG1 via heterodimerization with retinoid X receptor (RXR) [137]. 
Cholesterol transported by HDL is taken up by hepatic scavenger receptor class B type1 
(SR-B1) in the liver [138, 139]. Cholesteryl ester transfer protein (CETP) mediate transfer 
of cholesteryl esters from HDL to apoB-containing lipoproteins (LDL or VLDL) in 
exchange for triglycerides [140]. ApoA1 has been shown to reduce vascular inflammation 
in in vitro and in vivo studies [141, 142]. Recently a mimetic peptide of apoA1 with 
phospholipids, ETC-642 was shown to decrease adhesion molecule expression in collared 
rabbit carotid arteries, suppress inflammation via NF-κB signalling pathway [143].  
Liver and intestine are the major organs responsible for HDL synthesis, dysfunction of 
either of these organs under inflammation can lead to decreased profile of plasma HDL 
[144-146]. During infection and inflammation serum levels of HDL and apoA1 are 
decreased [10-13]. The proinflammatory cytokine TNF, which plays a major role in the 
pathogenesis of CD has been shown to decrease HDL cholesterol efflux to apoA1 by 
attenuating intestinal ABCA1 expression [147-150]. Consistent with this, clinical studies 
show a significant decrease in HDL-cholesterol in patients with IBD [14]. Furthermore, 
during inflammatory conditions, HDL is remodelled to an acute phase HDL with reduction 
in phospholipids and cholesterol esters and an increase in free cholesterol, triglycerides and 
free fatty acids which increasingly associate with SAA (serum amyloid A) and is 
proinflammatory [151-153].  
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1.8 Autophagy - a survival mechanism during cellular stress 
Autophagy refers to an evolutionary conserved cellular degradation mechanism that 
involves engulfment of cytoplasmic contents, delivery to the lysosome where they are 
degraded. It is upregulated in response to signals such as growth factor deprivation, 
pathogen infection, starvation, ER stress, and accumulation of unfolded proteins. 
Autophagy has acquired much attention in recent times for its ability to increase cell 
survival during periods of stress via catabolism of subcellular proteins, organelles and 
cytoplasmic components that generate free fatty acids, amino acids and nucleotides. 
Autophagy has been implicated in immunity, aging, cancer, neurodegenerative disorders 
and infectious diseases [154-156]. Autophagy contributes to immunity by directly 
removing pathogens, presenting these to adaptive immune system via MHC-II restricted 
antigen presentation and by supporting lymphocyte survival as well as homeostasis of T-
cells, B-cells and Paneth cells and thereby mediate cytokine production [157-160]. 
Autophagic substrates include long lived proteins such as GAPDH ( glyceraldehyde-3-
phosphate dehydrogenase). Also organelles such as mitochondria, endoplasmic reticulum, 
excess peroxisomes and mature ribosomes are targeted for lysosomal degradation by 
autophagosomes [161-166].  
35 autophagy related (ATG) genes have been identified. Autophagosomes are 
characterized by double membrane vesicles which can originate from ER, golgi complex, 
mitochondria or plasma membrane, the formation of which is mediated by ubiquitination-
like conjugation systems [167-170].  Microtubule associated protein light chain 3 (LC3) 
represent the mammalian ortholog of yeast ATG8. Lipidation of ATG8 (LC3) where 
ATG8 is conjugated to phosphatidyl-ehtanolamine mediates elongation of the isolation 
membrane and ATG5-ATG12-ATG16 mediates closure and fusion of autophagosomes 
with lysosomes to form degradative autolysosomes. Under active autophagy, cytoplamic 
LC3-I (18 Kda) is converted to a membrane bound phosphatidyl-ethonolamine-conjugated 
form LC3-II (16 Kda) that accumulates on autophagic vesicles [171-173] . Increase in 
LC3II is measured to quantify active autophagy. The process of autophagy is dependent on 
Beclin1 and class III phosphatidylinositol 3-kinase (PI3K) [174-176]. In genome wide 
association studies, three loci containing autophagy related genes ( ATG16L1, IRGM and 
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LRRK2) was shown to associate with CD, also ATG16L1 and IRGM  in UC [177-180]. 
ATG16L1 deficiency in mouse models leads to Paneth cell abnormalities with higher 
expression of pro-inflammatory mediators [160]. In addition, a role of autophagy in 
protecting against toxic products of pathogens such as Vibrio cholerae cytolysin, Bacillus 
anthracis lethal toxin and Helicobacter pylori vacuolating toxin has been described [181-
183]. 
 
Figure 6: Schematic diagram of macro autophagy 
(adapted from [184] ) 
The autophagy system includes Serine/Threonine kinases ULK1 and ULK2 (ATG1) mediating 
nucleation and activation of autophagy specific class III phosphatidylinositol 3- kinase (PI3K) 
complex PIK3C3/VPS34-BECLIN1 which recruit two ubiquitin like conjugates, ATG12-ATG5-
ATG16L1 complex and LC3 to the outer membrane, which is responsible for elongation of the 
isolation membrane and enclosure of the autophagosome [173, 185-189]. During this process, the 
phagophore engulf cytoplasmic constituents including organelles and finally fuse with the 
lysosome degrading the contents. 
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2 AIMS OF THE STUDY 
 
The following projects were included in my thesis. The aims of which are listed 
below: 
 
 In project 1 “Association of genetic variation in the NR1H4 gene, encoding the 
nuclear bile acid receptor FXR, with inflammatory bowel disease”, we aimed to 
investigate the association between genetic variants of FXR and IBD. Five FXR single 
nucleotide polymorphisms - two common SNPs and three rare variants were 
genotyped using Taqman allelic discrimination assays in a well-sized IBD vs. non-
IBD cohort. 
 
 Project 2 “HDL and its major protein ApoA1 suppress intestinal inflammation” 
aimed at elucidating the role of HDL/ApoA1 in intestinal inflammation. An in vitro 
model using colon adenocarcinoma cell line T84 was used and an in vivo DSS colitis 
model with ApoA1 knockout and ApoA1 transgenic mice was studied comparative to 
wild-type mice. 
 
 Project 3 “Anti-inflammatory effect of HDL and ApoA1 is mediated via activation 
of autophagic pathways” was designed to elucidate the molecular pathways by which 
HDL/ ApoA1 exerts its effects on intestinal cells. Regulation of autophagic pathways 
by HDL was investigated in T84 cells. 
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3  METHODS 
3.1 Association of genetic variation in the NR1H4 gene, encoding the 
nuclear bile acid receptor FXR, with inflammatory bowel disease [103] 
Study subjects 
The study population was European, and comprised of 591 healthy subjects and 547 IBD 
patients, from which 203 were diagnosed to suffer from UC and 344 from CD. The IBD 
subjects were recruited at the centers participating in the Swiss Inflammatory Bowel 
Disease Cohort Study (SIBDCS) [190]. For the IBD patients, the diagnosis of UC or CD 
was confirmed by the study investigators based on clinical presentation, endoscopic 
findings, and histology. Non-IBD controls were recruited from gastroenterological patients 
undergoing surveillance colonoscopy, and showed no symptoms of IBD. History of 
colorectal cancer was used as exclusion criteria for both IBD patients and non-IBD 
controls. All subjects provided their written informed consent to be included in the study. 
Ethical approvals were obtained from the local medical ethical committees of all study 
sites involved in the study: 1) The Swiss IBD Cohort Study (SIBDCS) (the participating 
centers are listed in http://ibdcohort.ch/index.php?id=94&L=2; ethical licence EK-1316). 
2) The Bioethical Committee at the Maria Sklodowska-Curie Memorial Cancer Centre and 
Institute of Oncology, Warsaw, Poland (ethical licences 25/2006 and 25/2006/2007). 
DNA extraction 
Genomic DNAs were extracted from either EDTA-blood or intestinal biopsies using the 
TRIzol reagent (Invitrogen, Basel, Switzerland) or the QIAamp DNA Mini Kit (QIAGEN, 
Hombrechtikon, Switzerland), respectively, according to the manufacturer’s instructions. 
The genomic DNAs were quantified with a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE) and diluted to a final concentration of 10 
ng/µl in nuclease free water.  
Genotyping of NR1H4 single nucleotide polymorphisms 
Genotyping of the five NR1H4 SNPs was performed using TaqMan allelic discrimination 
assays. A 7900HT Fast Real-Time PCR system (Applied Biosystems, Rotkreuz, 
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Switzerland) was used for cycling. Inventoried TaqMan SNP Genotyping Assays 
C_28000279_10, C_25598395, C_25598386_10, C_2366616_10, C_2800610_10 for the 
SNPs rs3863377, rs7138843, rs56163822, rs35724, and rs1086060, respectively were 
used for genotyping. Twenty nanograms of each genomic DNA was used per PCR reaction 
in a volume of 5 µl. The amplification run conditions were: Once 50°C for 2 min, once 
95°C for 10 min, 45 times 95°C for 15 sec, and 60°C for 1 min. 
Statistical analysis 
Statistical analysis for the individual SNP associations was performed using the software 
package SPSS 18 (SPSS Inc., Chicago, IL). The Chi-square test or Fisher’s exact test were 
used to determine associations between individual SNPs and subject phenotypes. A P-
value of <0.05 was considered as significant in non-corrected statistical tests and of <0.01 
after correction for multiple testing for the five SNPs (according to Bonferroni). The 
software package PSPower was used for retrospective power calculations 
(http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize). A retrospective 
power analysis of the applied statistical tests on genotype distributions revealed a power of 
0.525 for the SNP rs3863377 and a power of 0.323 for the SNP rs56163822, when 
considering a Bonferroni-corrected alpha level of 0.01 and the detected ORs as shown in 
Table 3 for the applied χ2-tests. Linkage disequilibria (LD) were calculated using D’ 
statistics and the software package Haploview (www.haploview.com). Haplotype 
predictions and frequency estimations were performed using the software tool FAMHAP  
(www.famhap.meb.uni-bonn.de). FAMHAP software performs permutation test on 
associations between estimated haplotypes and the affection state based on Monte Carlo 
simulations. The expectation maximization (EM) algorithm was used to obtain maximum-
likelihood estimates of the haplotype frequencies in a group composed of cases and 
controls. Individuals with several possible haplotype explanations are assigned with a 
likelihood weight to each possible haplotype and its calculated frequency estimate. A 
contingency table is constructed summing up all individuals’ weighted haplotype 
explanations for each haplotype and the chi-square statistics computed. The corresponding 
P-value is assessed via Monte Carlo simulation, i.e. in each replication of the algorithm a 
sample composed of a subgroup of case and control samples is randomly drawn and 
permuted.  FAMHAP calculates the global P-value via Monte Carlo simulations, as the cell 
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counts used in the contingency table are based on haplotype frequency estimates with 
increased variances, and not on real haplotype counts, which, as a result, does not 
necessarily follow exactly a chi-square distribution [191, 192]. A value of P <0.05 was 
considered to be significant. Bonferroni-corrected P-values (P<0.006, corrected for eight 
haplotypes that FAMHAP represented relevant to test for) were defined as the significance 
level for single haplotype comparisons in the white sections of Tables 4 - 4.2. In addition, 
haplotypes in best reconstruction (not weighted) were listed for the case and control groups 
in Tables 4-4.2 (grey sections) and used for association analysis performing Fisher’s exact 
tests or, in case of high cell counts (11 or more), Chi-square tests. Bonferroni-corrected 
significance levels (p<0.0026, corrected for 19 haplotypes) were used for significance 
testing. 
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3.2 HDL and its major protein ApoA1 suppress intestinal inflammation 
Chemicals 
Deoxyadenosine 5′-[α-32P]-triphosphate (6,000 Ci/mmol) was purchased from Perkin 
Elmer (Schwerzenbach, Switzerland). Unless stated, other chemicals were purchased from 
Sigma-Aldrich (Buchs, Switzerland),. The luciferase Pathway Profiling System containing 
the pNF-κB-luc, and the control vector pTAL-luc were obtained from Clontech. 
Cell culture 
Human colon-derived T84 cells were cultured in DMEM/F-12 (Invitrogen, Basel, 
Switzerland). The media was supplemented with 10 % fetal bovine serum (FBS; 
Brunschwig, Basel, Switzerland), and 100 U/ml penicillin / 100 μg/ml streptomycin 
(Invitrogen). A  humidified atmosphere containing 5 % CO2 at 37 ºC was used for all cell 
culture.  
Isolation of HDL from Plasma 
Human HDL (1.063 < d < 1.21 kg/liter) was prepared by sequential ultracentrifugation of 
fresh normolipidemic plasmas of blood donors [193]. The purity of the lipoprotein 
preparation was verified by SDS-PAGE to be free of LDL or albumin. HDL was further 
lyophilized and dissolved in 5M guanidinium-HCl and dialyzed against 1X LDL-buffer 
(10x LDL buffer composition: 1.12g EDTA, 87.66g NaCl, filled up to 1l with ddH2O, pH-
7.4 ) by centrifugation (20 minutes, 13000 rpm) in microcons ( 10 Kda cut-off). 
RNA isolation, Reverse transcription, and real-time PCR 
T84 cells were treated with HDL (50-100 µg/mL) for 18 hours before treating with 25 
ng/mL TNF for 3 hours. Total RNA was isolated using TRIzol reagent (Invitrogen). Total 
RNA from animal tissues was isolated using the RNeasy Mini Kit and the automated 
sample preparation system Qiacube (Qiagen, Switzerland) as described by manufacturer. 
One to two µg of RNA was reverse transcribed with High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Rotkreuz, Switzerland), before real-time PCR 
analysis using the TaqMan assays Hs00174128_m1 (hTNF), Hs00174103_m1 (hIL8), 
Hs00164932_m1 (ICAM), Hs00222677_m1, human ACTB (beta-actin) endogenous 
control (Applied Biosystems), Mm00443258_m1 (mTNF), Mm00516023_m1 (mICAM), 
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4352341E_mACTB, murine (beta-actin) endogenous control for animal experiments, on a 
7900HT Fast Real-Time PCR system (Applied Biosystems). Constitutively expressed beta 
actin was measured as an internal standard for normalization. Comparative threshold cycle 
method was used to calculate the relative mRNA levels. The cycling conditions for 
Quantitative real time PCR was 95°C for 20s, 40 cycles of 95°C 1s and 60°C for 20 s with 
the TaqMan Fast Universal Mastermix. Within an experiment, all tests were performed in 
triplicates. The mRNA levels obtained in control conditions were set to one and other 
conditions are shown relative to this as well as to endogenous control beta-actin. 
Luciferase reporter assays 
To study the effect of HDL on TNF induced NF-κB responsive promoter activity, cells 
were co-transfected with 400 ng of the luciferase reporter constructs of NF-κB and 200ng 
of the expression plasmids pTAL-luc at a ratio of 3 µl FuGENE HD per 1 µg DNA.  
pcDNA3.1(+) vector was added, where appropriate to normalize the amount of DNA 
transfected. To control for transfection efficiency, 100 ng of the renilla luciferase (pRL-
CMV) reporter plasmid (Promega) were co-transfected. Cells were harvested 36 hours 
after transfection, and luciferase activity determined using the Dual Luciferase Assay 
System (Promega) and a Luminoskan Ascent microplate luminometer (Thermo Fisher 
Scientific, Wohlen, Switzerland). Reporter activities obtained for the empty pGL3basic 
corresponding to respective test condition, as well as for the test construct containing the 
promoter of interest, in the control conditions, were set to one and fold activities are shown 
relative to this. All experimental conditions were performed in triplicates and the 
experiments repeated for at least three times. 
Electrophoretic mobility shift assays (EMSAs) 
Oligonucleotides with 5-GATC overhangs were used for annealing NF- κB consensus for 
radioactive labelling by fill in reactions as described [194]. 
Top strand:       5-GATCAGTTGAGGGGACTTTCCCAGGC-3 
Bottom strand:  5-GATCGCCTGGGAAAGTCCCCTCAACT-3 
Five micrograms of nuclear protein prepared by using the NE-PER extraction kit (Pierce, 
Lausanne, Switzerland) was mixed with 50,000 cpm (1.0 ng) of the radioactive probe, and 
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protein-DNA complexes were allowed to form for 30 minutes at 30°C. In supershift 
experiments, 1 µg of the anti-NF- κB p65 antibody (C-20; Santa Cruz Biotechnology, 
SantaCruz, CA) was added to the extracts before binding reactions and incubated at 4°C 
for 1 hour prior to addition of radioprobes. The EMSA gels were run in 0.5 X Tris-borate-
EDTA at 200 V and processed as described for autoradiography [194].  
Animals 
Control strains designated wild type (WT), C57BL/6J, ApoA1 knockout (KO), B6.129P2-
Apoa1tm1Unc/J (-/-) mice and ApoA1 transgenic (Tg), C57BL/6-Tg(APOA1)1Rub/J mice 
were purchased from Jacksons laboratories (Bar Harbor, Maine 04609 USA).  
Induction of acute colitis 
Animal experiments were approved by the veterinary authorities of Zurich, Switzerland 
and were carried out according to Swiss animal welfare laws. Seven- to eight week-old 
female C57BL/6J-Fue mice (wild type, WT), female ApoA1 knockout mice (ApoA1 KO) 
and female ApoA1 transgenic (Tg) were used for the experiments and housed in a 
specified pathogen-free facility in individually ventilated cages. Acute colitis was induced 
with 2.5% of Dextran sodium sulfate (DSS) (MP Biomedicals, Illkirch, France) in drinking 
water  [195]. The animals were divided into six groups, three DSS groups and three water 
control groups with six individuals each in such a way that the average weight was similar 
between the groups. Animals were fed food and water with or without DSS ad libitum.  
Determination of colonoscopy score 
For colonoscopy scoring we determined mucosal bleeding, abundant fibrin, altered 
vascular pattern, nontransparent mucosa (granularity), and stool composition. Animals 
were anesthetized intraperitoneally with a mixture of 90–120 mg/kg body weight ketamine 
(Vétoquinol, Bern, Switzerland) and 8 mg/kg body weight xylazine (Bayer, Lyssach, 
Switzerland), and were examined as described previously [196, 197]. The endoscope was 
introduced with a lubricant (2% lidocaine) through anus in the sedated mouse, the colon 
was gently inflated with air and photographs of the colon were taken. Recording was 
performed with the Karl Storz Tele Pack Pal 20043020 (Karl Storz Endoskope, Tuttlingen, 
Germany).  
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Determination of histological score and colon length 
From the distal third of the colon, 1 cm of colonic tissue was removed and fixed in 4% 
formalin overnight. Sections of the paraffin-embedded tissue were used for histological 
analysis, as described previously based on the loss of crypts, loss of goblet cells, 
infiltration of lymphocytes, thickening of submucosa/mucosa. [195, 198] Histological 
examination was performed by an independent, blinded investigator.  
Myeloperoxidase activity assay 
Colon specimens were washed with 1× PBS and homogenized with a tissuelyzer (Qiagen) 
in 50 mM phosphate buffer (pH 6.0) and 0.5% hexadecyltrimethylammonium bromide 
(Sigma Aldrich). Three freeze and thaw cycles were performed. Homogenates were then 
centrifuged for 2 min at maximum speed; 20 μl of the supernatant was mixed with 280 μl 
of 0.02% dianisidine (in 50 mM phosphate buffer, pH 6.0, and 0.0005% H2O2; Sigma 
Aldrich) and transferred to a 96-well plate in duplicates. After 20 min, absorbance was 
measured at 460 nm. Protein concentration of the supernatant was determined by 
bicinchoninic acid protein assay (BCA). Myeloperoxidase (MPO) activity (indicated as 
arbitrary units) was calculated as mean absorbance (460 nm) per incubation time per 
protein concentration in grams. 
Statistical analysis 
The cell-based experiments were repeated for at least three times independently, and 
representative experiments are shown. All quantitative data are shown as means ± standard 
deviations of n experiments. Differences between experimental groups were analyzed by 
one-way ANOVA with Tukey’s post hoc test. A p value <0.05 was considered significant. 
For the correlation of mRNA expression levels in human tissue material, logarithmic 
values of mRNA levels were analyzed using linear regression. All statistical analysis was 
performed using GraphPad Prism (GraphPad Software, San Diego, CA). For animal study, 
six animals could be analyzed per group. Statistical analysis of weight loss, colon length, 
histological score, colonoscopy score and MPO was performed by ANOVA and a Post 
Hoc Multiple Comparison by Tukey.   
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3.3 Anti-inflammatory effect of HDL and ApoA1 is mediated via 
activation of autophagic pathway 
Western blotting 
Cells were grown on 6 well plates for 24 hours, followed by incubation with HDL or 
ApoA1 for 18 hours prior to treatment with 25 ng/mL TNF for 3 hours. Cells were washed 
once with 1X PBS and then harvested into Ripa buffer with complete mini (protease 
inhibitor) 
Transfection of cells with siRNAs 
Cells were seeded at 400000 cells per well onto 24-well plates, and transfected with 
ABCA1, SRB1 and LC3 SiGenome SMARTpool (Dharmacon, Lafayette, CO) or 
siCONTROL non-targeting siRNA #2 (Dharmacon) at a final concentration of 50 nM 
using the TransIT-TKO reagent (Mirus Bio LLC, LabForce). The transfections were 
repeated after 24 hours, and the cells were harvested in 1 ml TRIzol (Invitrogen), 24 hours 
after the second transfection. 
Isolation and Culture of Human Colonic Lamina Propria Fibroblasts (CLPF) 
Primary human CLPF cultures were derived from surgical specimens of patients with 
active CD and cultured as described previously [199]. The fibroblasts were cultured in 
DMEM containing 10% FCS, penicillin (100IU/mL), streptomycin (100 µg/mL), 
ciprofloxacin (8 µg/mL), gentamycin (50µg/mL), and amphotericin B (1 µg/mL). Genomic 
DNA was isolated from cultured fibroblasts and genotyped for ATG16L1 variant using 
predesigned genotyping assays (Applied Biosystems, Foster City, CA) and TaqMan 
technology. Written informed consent was obtained before specimen collection, and 
studies were approved by the local Ethics Committee. 
Confocal Microscopy 
After treatment of cells with HDL for 18 hours and TNF for 3 hours, cells were washed 
with PBS and fixed with 4% paraformaldehyde for 15 minutes. For LC3 staining, fixed 
cells were washed with PBS, permeabilized in 100% methanol at -20°C for 10 minutes, 
washed wit PBS and blocked with 3% BSA for I hour at room temperature. Cells were 
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subsequently incubated with LC3 antibody (1:200) dilution overnight at 4°C. After 3 
TBST washes, cells were incubated with Alexa 488 conjugated secondary rabbit antibody 
for 1 hour at room temperature and then washed three times in TBST before mounting with 
antifade DAKO. Cells were observed with a CLSM Leica SP5 laser scanning confocal 
microscope and analyzed using Leica confocal software (LAS-AF Lite). 
Gold labeling of HDL 
Colloidal gold was prepared as described [200] using a particle size of 8 nm. For the 
conjugation of HDL to colloidal gold, 10 ml of a monodisperse gold solution was added to 
16 µL lipoprotein solution containing 50 mg lipoprotein protein/ml in phosphate buffer and  
pH adjusted to 5.5. Excess of lipoprotein was removed by centrifugation at 9,000 g for 20 
min against glycerine and dialysed in EDTA buffer to remove glycerine. 
Incubation of HT29 with gold labeled HDL 
Inorder to follow the uptake of HDL into intestinal cell line, colon carcinoma HT29 cells 
were incubated with gold labeled HDL for 18 hours. The cells were washed in PBS and 
fixed with 2.5% glutaraldehyde + 0.8% formaldehyde in  50mM NaCL and 0.1M 
Phosphate buffer for 2 hours at room temperature, post fixed in 1% OsO4 (50mM 
Phosphate buffer) at 4°C for one hour, block stained with 1% Uranyl acetate in water for 1 
hour after which the tissue was dehydrated in ethanol (70-100%, 30 minutes) and 
propylene oxide (2 X 20 minutes), polymerized and embedded in epon araldite. Electron 
microscopy was performed on a Philips CM100 transmission electron microscope. 
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4 RESULTS 
4.1 Association of genetic variation in the NR1H4 gene, encoding the 
nuclear bile acid receptor FXR, with inflammatory bowel disease [103] 
Study population 
The study population was European and consisted of more women (806) than men (332). 
Detailed demographic data is given in Table 1. 
 
Table 1 Demographic data of the population included in the analysis (adapted from [103]) 
Characteristics non-IBD IBD CD UC 
Population 591 (51.9%) 547 (48.1%) 344 (30.2%) 203 (17.8%) 
Mean age (± SD) 55.7 (± 12.6) 42.6 (± 15.1) 40.9 (± 14.9) 45.4 (± 14.9) 
Median age   59  41 39 44 
Minimum age  20 16 16 18 
Maximum age 81 82 79 82 
 
NR1H4 sequence variability 
All five NR1H4 variants selected for the study are single nucleotide substitutions, 
previously identified within the NR1H4 gene (www.ncbi.nlm.nih.gov/snp/). Three of these 
SNPs can be considered as rare variants: rs3863377, rs56163822, rs7138843, with 
reported minor allele frequencies (MAF) of 4%, 2.2%, and 0.9%, respectively. The other 
two variants, rs10860603 and rs35724, are common SNPs, with minor allele frequencies 
of 20.5% and 40.8% (www.ncbi.nlm.nih.gov/snp/) in European individuals. The obtained 
allele and genotype frequencies are given in Tables 2 and 3, respectively. 
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Genetic variation in the NR1H4 gene and IBD 
The NR1H4 SNP variants rs3863377 and rs56163822 were found to be significantly 
associated with IBD when considering an uncorrected significance level of p<0.05. Upon 
statistical analysis of the allele (Table 2) and genotype (Table 3) frequencies, we observed 
that the NR1H4 variant rs3863377 is significantly less frequent in IBD cases than in non-
IBD controls (allele frequencies: P=0.004; wild-type vs. SNP carrier genotype frequencies: 
P=0.008) even when considering an Bonferroni-corrected significance level of P<0.01. 
Upon subgrouping the IBD patients, the significance of the inverse association of the 
rs3863377 SNP remained for the CD patients when considering an uncorrected 
significance level of P<0.05 (allele frequencies: P=0.015; wild-type vs. SNP carrier 
genotype frequencies: P=0.024), but not for the UC group (allele frequencies: P=0.075; 
wild-type vs. SNP carrier genotype frequencies: P=0.083). Conversely, the variant 
rs56163822 is less prevalent in non-IBD subjects than in IBD patients (allele frequencies: 
P=0.027; wild-type vs. SNP carrier genotype frequencies: P=0.035); an observation, which 
is, however, not significant, when considering a corrected significance level of P<0.01. 
Upon subgrouping the patient cohort according to IBD subtypes, the uncorrected 
association remained only significant for the UC group (allele frequencies: P=0.036; wild-
type vs. SNP carrier genotype frequencies: P=0.034). Upon adjustment for age and gender, 
the uncorrected significance (P<0.05) of genotype frequency association with IBD 
remained for rs3863377, but was reduced to P>0.05 for rs56163822. There were no 
significant differences in the allele frequency distribution between the subject groups for 
NR1H4 variants rs7138843, rs10860603, and rs35724. 
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Table 2 Allele frequencies of the NR1H4 variants in the study population  
SNP rs3863377,  (G  A) 
 Case                MAF (%)               p                  OR                 CI                    Reported MAFs1                                                                                                                                                                                               
non-IBD        32 (2.9)                                                                                      4.0% 
 IBD                10 (1.1)               0.004**          0.37          0.18-0-75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 CD                  6 (1.1)               0.015*           0.36         0.15- 0.86          
 UC                  4 (1.2)                0.075              0.38          0.14-1.10 
SNP rs56163822, (G T)  
Case                 MAF (%)               p                   OR                CI                   Reported MAFs1   
non-IBD          20 (1.7)                                                                                    2.2% 
IBD                 34 (3.2)              0.027*            1.86          1.06-3.25            
CD                  20 (2.9)              0.081              1.74           0.93-3.25              
UC                  14 (3.5)              0.036*           2.07            1.03-4.13 
SNP  rs7138843,  (A  T) 
 Case                MAF (%)                p                                                                Reported MAFs1                       
non-IBD         17 (1.7)                                                                                      0.9% 
 IBD                21 (2.4)                 ns                                                        
 CD                 11 (2.0)                   ns                                                        
 UC                 10 (3.0)                  ns 
SNP  rs10860603, (G  A) 
 Case                MAF (%)                p                                                                Reported MAFs1                       
non-IBD         173 (14.9)                                                                                  20.5 % 
 IBD                139 (12.9)            ns                                                        
 CD                  90 (13.4)              ns                                                        
 UC                  49 (12.3)              ns 
SNP  rs35724,  (G  C) 
 Case                MAF (%)                p                                                                Reported MAFs1                       
non-IBD         466 (40.0)                                                                                  40.8% 
 IBD                471 (43.8)            ns                                                        
 CD                 299 (44.4)            ns                                                        
 UC                 172 (43.0)            ns 
MAF, minor allele frequencies; 1According to the National Center for Biotechnology Information (NCBI) SNP 
database *, p<0.05; **, p<0.01 , p’, p value adjusted to age and gender         
OR, odds ratio; CI, confidence interval, WT: wildtype, Het: heterozygous SNP carrier, Hom: homozygous 
SNP carrier (adapted from [103])  
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Table 3 Genotype frequencies of the NR1H4 variants in the study population  
SNP rs3863377 (G A) 
                   WT [GG]       Het [GA]     Hom [AA] (%)      p               p’           OR           CI               χ2 
non-IBD      506 (94.4)      28 (5.2)           2 (0.4)                                                                                      0.14 
IBD              438 (97.8)      10 (2.2)           0                     0.008**    0.022*      0.39      0.19-0.80           0.01 
CD                 271 (97.8)       6 (2.2)            0                     0.024*      0.031*      0.37      0.15-0.91          0.01 
UC                167 (97.7)       4 (2.3)             0                     0.083        0.066        0.40      0.14-1.16           0.01 
SNP rs56163822 (-1G T) 
 
                  WT [GG]       Het  [GT]      Hom [TT] (%)      p               p’          OR            CI                χ2 
non-IBD      560 (96.6)       20 (3.4)           0                                                                                              0.04 
IBD             505 (93.9)        33 (6.1)            1 (0.09)         0.035*      0.451        1.83      1.04-3.23             0.00 
CD               319 (94.4)       19 (5.6)              1 (0.09)          0.115        0.846        1.67      0.88-3.17            0.00 
UC                186 (93.0)       14 (7.0)            0                   0.034*      0.154         2.11        1.04-4.26               0.13 
 SNP rs7138843 (A T) 
                  WT [AA]       Het [AT]      Hom [TT] (%)       p              p’          OR            CI                 χ2 
non-IBD      495 (96.7)       17 (3.3)           0                                                                                            0.03 
IBD             417 (95.2)        21 (4.8)           0                     0.248        0.772      1.47      0.76-2.82          0.06 
CD              261 (96.0)        11 (4.0)           0                     0.603        0.612      1.23      0.57-2.66             0.04 
UC              156 (94.0)        10 (6.0)           0                     0.122        0.981      1.87      0.84-4.16              0.10 
SNP rs10860603 (G A) 
                    WT [GG]       Het [GA]      Hom [AA] (%)      p              p’          OR            CI                χ2 
non-IBD     424 (72.8)       143 (24.6)      15 (2.6)                                                                                  0.49 
IBD             407 (75.8)        121(22.5)      9 (1.7)           0.261         0.384       0.857    0.655-1.12        0.00 
CD              254 (75.4)         76 (22.5)      7 (2.1)           0.403         0.611       0.877    0.645-1.19        0.22 
UC              153 (76.5)         45 (22.5)      2 (1.0)           0.312         0.521       0.824    0.567-1.19        0.43 
SNP rs35724 (C G) 
                    WT [GG]       Het [GC]      Hom [CC] (%)      p              p’          OR            CI                 χ2 
non-IBD      217 (37.3)       264 (45.4)     101 (17.3)                                                                              1.78 
IBD             177 (32.9)        251 (46.7)     110 (20.4)       0.125       0.209       1.213     0.948-1.55       1.47 
CD              111 (32.8)        155 (45.9)      72 (21.3)        0.175       0.279       1.216     0.917-1.61       1.68 
UC              66 (33.0)          96 (48.0)        38 (19.0)        0.277       0.233       1.207     0.860-1.69       0.09 
OR: odds ratio; CI: confidence interval 
WT: wildtype, Het: heterozygous SNP carrier, Hom: homozygous SNP carrier, χ2, Hardy-Weinberg equilibrium 
χ2  tests were carried considering hetero- and homozygous SNP carriers as one group in case and control populations 
*, p<0.05; **, p<0.01 , p’, p value adjusted to age and gender   (adapted from [103]) 
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NR1H4 haplotype analysis (adapted from [103]) 
All individuals, for whom genotype determination could be performed for all five NR1H4 
SNPs under study, were included in the haplotype prediction analyses. Four hundred and 
eighty-six non-IBD cases, along with 241 CD patients and 148 UC patients were thus 
haplotyped. Nineteen haplotypes and up to thirty-nine diplotypes were predicted by the 
software FAMHAP to exist in the studied cohort. NR1H4 haplotypes were significantly 
differentially distributed in the IBD and control groups (Table 4, P=0.003) upon global 
haplotype distribution analysis. This observation held partially true upon stratification 
according to disease subtype. Here, the haplotype frequencies differ significantly between 
the UC patients and the non-IBD control group (Table 4.1, P=0.004), but not between the 
CD patients and the control subjects (Table 4.2, P=0.079). We particularly note that the 
haplotype 14, GTTGC, is predicted to occur significantly (P=0.005) more frequently in the 
UC group in comparison with the non-IBD cohort. This haplotype harbours the more 
frequent allele G at the first SNP position rs3863377, which was shown to be significantly 
associated with IBD even after Bonferroni correction. It is thus a possible risk haplotype 
for the development of IBD, although we note that the overall frequency for this haplotype 
is rather low. Upon best reconstruction analysis the significance of the association of the 
haplotype 14 GTTGC with the UC group was, however, lost (P=0.012) (Table 4.1, grey 
section). No significant associations were observed for the predicted diplotype patterns and 
IBD. As shown in the LD plot (Fig 7), there was no significant linkage disequilibrium 
between any of the five NR1H4 SNPs studied. 
 A plot with D’ values  
 
Colour scheme:  
D’ < 1 and LOD < 2, white 
D’ = 1 and LOD < 2, blue  
D’ < 1 and LOD > 2, pink 
 
Figure 7:  Pairwise linkage disequilibrium calculations between the five NR1H4 SNPs under study 
in the non-IBD population  
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4.2 HDL and its major protein ApoA1 suppress intestinal inflammation 
HDL has anti-inflammatory effects in vitro 
We have used human colon carcinoma cell line T84 which exhibit phenotype similar to 
mature enterocytes including differentiation into absorptive cells and polarization for in 
vitro experiments. 
 
HDL suppresses pro inflammatory mediators TNF, IL-8 and ICAM in T84 cells. 
In order to study potential anti-inflammatory effects of HDL in vitro, we treated T84 cells 
with HDL for 18 hours and subsequently stimulated the cells with  25 ng/mL TNF for 3hrs.  
As  read-out, mRNA expression of pro-inflammatory mediators TNF and IL-8 as well as 
ICAM was quantified in the presence and absence of HDL. TNF incubation induced 
mRNA expression of TNF, IL-8, and ICAM by factors 178, 127 and 830, respectively (all 
P<0.001). Pre-treatment of these cells with HDL significantly decreased TNF-induced 
mRNA expression of TNF, IL-8 and ICAM by 59%, 31% and 50%, (all P<0.001) (Fig 8.).  
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Cells were treated with HDL (200 µg/mL) for 18hrs after which 25 ng/mL TNF was added for 3 
hours. mRNA expression of TNF, IL8 and ICAM was quantified by RT-PCR and normalized to 
actin. Each bar represent mean + SD, n=3, *** P<0.001 
  
Figure 8 : HDL suppressed mRNA expression of TNF, IL-8 and ICAM-1 
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HDL suppressed TNF mediated induction of TNF mRNA expression in a concentration 
dependent manner by 20% in the presence of 50 µg/mL HDL and to 60% in the presence 
of 200 µg/mL HDL (Fig 9,  P<0.001).  
 
Figure 9: HDL suppressed inflammation in a concentration dependent manner 
T84 cells were treated with HDL for 18 h after which 25 ng/mL TNF was added for 3 hours. 
mRNA expression of TNF was quantified by RT-PCR and normalized to actin. Each bar represent 
mean + SD, n=3, *** P<0.001 
HDL decreases phosphorylation of IκB kinase (IKK)  
We further investigated the mechanism by which HDL suppress proinflammatory cytokine 
secretion. NF-κB is a key transcription factor that regulates genes such as TNF, IL-8 or 
ICAM, involved in immune and inflammatory responses [201]. In non stimulated cells, 
NF-κB is held inactive in the cytoplasm bound to the inhibitor protein IκB. The 
translocation of NF-κB to the nucleus is preceded by phosphorylation of IκB kinase 
complex (IKK). Upon stimulation with NF-κB inducers such as TNF, IκB is rapidly 
phosphorylated on its serine residues (S32 and S36) by IKK, ubiquitinated and degraded 
by 26S proteasome [202, 203]. In order to investigate the role of HDL in the NF-κB 
pathway, we extracted whole cell protein from T84 cells treated with HDL for 18 h in the 
presence and absence of TNF (25 ng/mL). HDL decreased phosphorylation of IKK, in T84 
cells (Fig 10) slightly but not significantly. TNF preincubation increased phosphorylation 
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of IKK by 46%. The TNF induced IKK posphorylation was reduced , when the cells were 
pretreated with HDL by 70%. 
 
Figure 10: HDL decreased phosphorylation of IKK (IkB kinase) 
Whole cell protein extracts from T84 cells were immunoblotted for phosphorylated form of IKK. 
P-IKK arbitrary units represent ratio of p-IKK to actin and then normalized to the untreated control 
HDL suppresses TNF induced NF-κB responsive promoter activity in T84 cells 
As HDL prevents TNF induced expression of NF-kB dependent genes and TNF-induced 
activation of IKK, we next investigated whether HDL also prevents TNF induced NF-κB 
responsive promoter activity. T84 cells were transfected with luciferase constructs 
expressing an NF-κB responsive element along with corresponding controls (empty vector-
pTAL-luc). 24 hours after transfection, the cells were incubated with HDL (100 µg/mL) 
for 18 hours, after which 25 ng/mL TNF was added for 6 hours. The cells were harvested 
and analysed by a dual luciferase reporter assay. As shown in Fig 11, HDL itself inhibited 
NF-κB luciferase activity by 26% (P<0.05).  TNF pre-incubation almost tripled luciferase 
activity in our assay.  Preincubation with HDL significantly decreased the TNF induced 
NF-κB responsive promoter activity by 50% (P<0.001).  
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Very similarly ApoA1 also decreased the effect of TNF stimulation by 50% (P<0.001) 
indicating that the protein component of the lipoprotein is responsible for mediating the 
anti-inflammatory effect. 
 
Figure 11: HDL suppresses TNF induced NF-κB responsive promoter activity 
T84 cells were transiently transfected with plasmid containing NF-κB responsive promoter region 
cloned upstream of a luciferase reporter gene. TNF significantly increased NF-κB responsive 
promoter activity, preincubation of cells with HDL/ApoA1 significantly suppressed TNF induced 
NF-κB responsive promoter activity. n=3; *, P<0.05, ***, P<0.001. 
We further investigated whether pretreatment of T84 cells with HDL affects the nuclear 
translocation of NF-κB in stimulated or unstimulated cells. As assayed by EMSA, using a 
radiolabeled NF-κB binding motif consensus, under control conditions as well as pre-
treatment with only HDL or ApoA1, no nuclear translocation was visible. As expected 
TNF caused a strong nuclear translocation of  NF-κB (Fig 12, lane 3). Pretreatment of T84 
cells with HDL or ApoA1 decreased TNF induced NF-κB DNA binding activity clearly 
(Fib 12 lanes 4 and 6).  A supershift was observed upon incubation of nuclear extracts with 
the P65 antibody. 
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Figure 12: HDL/ApoA1 decreased TNF induced NF-κB DNA binding activity 
Nuclear extracts from T84 cells were subjected to EMSA using a 32P labelled NF-κB consensus. 
The arrow head indicates binding reaction of TNF to NF-κB consensus. HDL/ApoA1 decreases 
TNF binding to NF-κB. A supershift was observed upon incubation of nuclear extracts with P65 
antibody; n=3. 
The anti-inflammatory effect of HDL is mediated by its main protein ApoA1 
ApoA1 is the major protein constituent of plasma HDL. We next tested if pretreatment of 
T84 cells with ApoA1 could suppress TNF induced NF-κB responsive promoter activity 
and mRNA expression of target genes. Pretreatment of T84 cells with 100 µg/mL ApoA1 
led to a 37% decrease in TNF induced NF-κB responsive promoter activity (P<0.001) (Fig 
11). mRNA expression of TNF, IL-8 and ICAM was also significantly decreased by 73%, 
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54% and 51% respectively (P<0.001), when T84 cells were incubated with ApoA1 (prior 
to TNF addition (Fig 13). The suppression of TNF by ApoA1 was concentration dependent 
(Fig 14 ) ranging from 35% in the presence of 50 µg/mL ApoA1 and to 73% in the 
presence of 200 µg/mL ApoA1 (P<0.001). 
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Figure 13: ApoA1 suppresses mRNA expression of TNF, IL-8 and ICAM 
Cells were treated with ApoA1 (100 µg) for 18hrs after which 25 ng/mL TNF was added for 3 
hours. mRNA expression of TNF, IL8 and ICAM was quantified by RT-PCR and normalized to 
actin. Each bar represent mean + SD, n=3, *** P<0.001. 
 
 
Figure 14: ApoA1 suppresses inflammation in a concentration dependent manner 
Cells were treated with ApoA1 (100 µg) for 18hrs after which 25 ng/mL TNF was added for 3 
hours. mRNA expression of TNF was quantified by RT-PCR and normalized to actin. Each bar 
represent mean + SD, n=3, *** P<0.001. 
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Weight loss was monitored during the 7 day course of acute colitis. Upon treatment with 
DSS and in comparison with the water-drunk control animals, the body weight decreased 
significantly in WT mice and ApoA1 KO mice (P<0.001) but not in ApoA1 Tg mice (Fig 
15). Colon length was significantly shortened in all animals with DSS treatment compared 
to their respective water controls. However the shortening was most pronounced in WT 
mice (P<0.001) and ApoA1 KO mice (P<0.001) and least pronounced in ApoA1 Tg mice 
(P<0.05). 
 
Figure 15: Assessment of clinical colitis parameter: weight loss and colon shortening upon DSS 
induced colitis 
The weight loss was monitored over 8 days, calculated as relative change of body weight in % to 
day one. ApoA1 KO and WT mice lost more weight than ApoA1 Tg upon DSS. The colon length 
was significantly decreased in mice recieving DSS within the groups. Each bar represent mean + 
SEM, n=6, * P<0.05, *** P<0.001. 
ApoA1 reduces colonic inflammation in vivo 
To investigate whether ApoAI can protect colitis associated intestinal tissue damage in 
vivo, an acute dextrane sodium sulfate (DSS) colitis model was applied to wild type mice 
(WT), ApoA1 knock-out mice (ApoAI KO) and mice transgenic for human ApoAI 
(ApoAI-Tg). Mice received either pure water or water supplemented with 2.5% DSS for a 
period of 7 days. Mucosal damage was assessed by miniendoscopy and quantified  by 
using the MEICS score (Fig 16).  
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Figure 16: Miniendoscopy of distal colon 
Colonoscopy was performed on day 8 prior to sacrificing mice. Representative images of 
colonoscopy of water and DSS treated mice are shown. Murine endoscopic index of colitis severity 
(MEICS) was scored based on the images and plotted as box plot. Severe disruption of epithelium 
was observed in ApoA1 KO mice recieving DSS where as ApoA1 Tg mice displayed an intact 
surface with still formed stool compared to WT upon DSS colitis. Each bar represent mean + SEM, 
n=6, * P<0.05, *** P<0.001 
Interestingly the endoscopic score indicated that the mucosa was significantly damaged in 
ApoA1 KO mice receiving water only (P<0.01) as compared to WT and ApoA1 Tg mice 
receiving pure water. Mucosa of WT and ApoA1 Tg mice receiving only water displayed a 
smooth, well vascularized mucosa, a solid stool was visible where as ApoA1 KO mice had 
low levels of diarrhea and thickening of the mucosal walls. Upon DSS treatment severe 
mucosal damage occurred in all animals (P<0.001) compared to the water controls. 
Notably ApoA1 Tg mice demonstrated significantly less damage than WT and ApoA1 KO 
mice upon DSS treatment (P<0.05). Upon DSS treatment, ApoA1 KO mice displayed a 
mucosa with cobblestone-like appearance and increased bleeding as compared to ApoA1 
Tg mice.  
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To assess the severity of colitis, we also analysed distal colon tissue specimens 
histologically. As shown in Fig 17, a total loss of crypt structure with increased infiltration 
of lymphocytes into the submucosa and thickening of the bowel wall were observed in the 
DSS groups as compared to the respective water groups (P<0.001). Upon DSS treatment, 
the total histological score was significantly increased for ApoA1 KO mice compared with 
WT mice (P<0.05) and ApoA1 Tg mice (P<0.01). ApoA1 KO mice displayed significantly 
more infiltration of inflammatory cells compared to WT mice (P<0.001) and ApoA1 Tg 
mice (P<0.05). 
 
Figure 17: Hematoxylin and eosin (HE) staining of terminal colon 
Histological sections were scored based on morphology of epithelia, loss of goblet and crypt cells 
and infiltration of inflammatory cells. HE section of ApoA1 KO recieving DSS displayed severe 
barrier breakdown with extensive infiltration reaching the lamina muscularis mucosae. The total 
histological score calculated as the sum of epithelium and infiltrate score is plotted. Each bar 
represent mean + SEM, n=6, * P<0.05, ** P<0.01, *** P<0.001. 
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Migration of leukocytes to the site of injury is a major event in inflammation. 
Spectrometric determination of myeloperoxidase (MPO) activity is a quantitative 
assessment of neutrophil infiltration. The relative MPO activity in tissue homogenates was 
significantly higher in each DSS group than in its corresponding water group (P<0.001) 
(Fig 18). However, tissue homogenates of DSS-treated ApoA1 Tg mice showed 
significantly lower MPO activity than those of DSS-treated ApoA1 KO mice and WT mice 
(P<0.001). 
 
Figure 18: Myeloperoxidase activity in mucosal homogenates of ApoA1 KO, Tg mice 
comparative to WT mice 
Relative MPO activity of each DSS group to its corresponding water groups was significantly 
increased in WT and ApoA1 KO mice. ApoA1 Tg displayed less MPO activity comparative to WT 
and ApoA1 KO, however did not reach significance. Each bar represent mean + SEM, n=6, *** 
P<0.001. 
Increased expression of TNF and ICAM in ApoA1 KO mice 
The mRNA expression of the proinflammatory cytokine TNF and the adhesion molecule 
ICAM was measured in whole colon tissues (Fig 19). Already in the absence of DSS, the 
expression of TNF and ICAM was increased in ApoA1 KO mice compared to WT mice 
(P<0.001 for TNF, ns for ICAM). Upon DSS feeding TNF and ICAM mRNA expression 
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increased significantly in all  animals (P<0.001) but most tremendously in ApoA1 KO 
mice. As the result TNF and ICAM expression in ApoA1 KO mice was 18 and 34 times, 
respectively, higher than in WT mice and 10 and 168 times, respectively, higher than in 
ApoA1 Tg mice (both P<0.001). 
 
 
Figure 19: mRNA expression of TNF and ICAM in colon tissue samples of ApoA1 KO , Tg and 
WT mice with and without DSS administration 
ApoA1 KO mice recieving DSS displayed significant increase in mRNA expression of TNF and 
ICAM where as ApoA1 Tg mice displayed lower expression levels of TNF and ICAM comparative 
to WT and ApoA1 KO upon DSS induced colitis. The mRNA expression was calculated relative to 
WT mice recieving water. Each bar represent mean + SEM, n=6, *** P<0.001.  
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4.3 Anti-inflammatory effect of HDL and ApoA1 is mediated via 
activation of autophagic pathway 
HDL induces autophagy in T84 cells by inhibiting phosphorylation of mTOR 
The phospholipid conjugation of cytosolic protein LC3I to membrane bound LC3-II is a 
reliable marker for autophagic activation. Autophagy induction was confirmed by western 
blotting and immunofluorescense analysis with anti-LC3 antibody. HDL induced 
concentration dependent accumulation of LC3-II (Fig 20). Consistent with this, HDL 
decreased phosphorylation of mTOR, a negative regulator of the autophagic pathway (Fig 
21). 
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Figure 20: HDL and ApoA1 induces LC3 in T84 cells 
T84 cells were incubated with HDL and ApoA1 for 18 hours. Whole cell proteins were extracted in 
RIPA buffer for western blot analysis. For immunofluorescence, the cells were fixed in 4% 
formaldehyde and stained for LC3; n=3. 
 
 
Figure 21: HDL and ApoA1 decreases phosphorylation of mTOR; n=2 
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Inhibition of autophagy reverses the anti-inflammatory effect of HDL 
To confirm that anti-inflammatory effect of HDL is mediated via autophagy, we pre-
treated T84 cells with autophagic inhibitors 3-methyl adenine (10mM) and Wortmannin 
(25nM) for 6 hours prior to HDL addition. The ability of HDL to suppress TNF induced 
NF-κB responsive promoter activity (Fig 22) as well as mRNA expression of TNF was 
decreased when autophagy was inhibited (Fig 23). In addition, SiRNA knock down of LC3 
decreased the anti-inflammatory effect of HDL, assessed by the ability of HDL to suppress 
TNF induced mRNA expression of TNF (Fig 24).  
 
Figure 22: Ability of HDL to suppress TNF induced NF-κB responsive promoter activity is 
decreased in the presence of PI-3 kinase inhibitor Wortmannin and autophagy specific class III PI-3 
kinase inhibitor 3-methyl adenine (3-MA); n=3. 
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Figure 23: Ability of HDL to suppress TNF induced mRNA expression of TNF is decreased in the 
presence of autophagy inhibitors 
T84 cells were incubated with 10 mM 3-methyladenine or 25 nM Wortmannin for 6 hours to 
inhibit PI-3 kinase, after which HDL was added for 18 hours prior to treatment with 25 ng/mL TNF 
for 3 hours. mRNA expression of TNF was quantified relative to actin; n=3. 
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SiRNA knockdown of LC3 reverses the anti-inflammatory effect of HDL 
 
  
 
 
Figure 24: SiRNA knockdown of autophagy gene LC3 decreases the anti-inflammatory effect of 
HDL 
T84 cells were transfected with 50 nM  control SiRNA or LC3 SiRNA. 48 hours after transfection, 
cells were incubated with HDL (100 µg/mL) and ApoA1(50 µg/mL) for 18hrs, after which 25 
ng/mL TNF was added to the cells. mRNA expression of LC3 and TNF was quantified relative to 
actin; n=3. 
RESULTS 
52 
 
Anti-inflammatory effect of HDL is reduced in human fibroblast with ATG16L1 
mutation 
Human fibroblasts harboring heterozygous (A/G) (CU 137) and homozygous (G/G) (CU 
138) mutation of ATG16L1 was compared to control fibroblast with both active alleles of 
ATG16L1 (A/A) (CU 403) to study the significance of autophagy gene ATG16L1 in the 
anti-inflammatory effect mediated by HDL. As shown in Fig 25 , the mRNA expression of 
TNF was significantly higher in fibroblast with ATG16L1 mutations upon incubation with 
TNF, the ability of HDL to suppress TNF induced mRNA expression of TNF was 
significantly reduced in homozygous and heterozygous variants of ATG16L1 comparative 
to control. In mutant fibroblast CU138 which has both alleles mutated, anti-inflammatory 
effect of HDL was significantly decreased comparative to CU137 which has one functional 
allele. 
 
Figure 25: mRNA expression of TNF in human fibroblast with ATG16L1 mutation 
Fibroblasts were treated with HDL for 18 hrs after which 25 ng/mL TNF was added to the cells. 
mRNA expression of  TNF was quantified relative to actin; n=3. 
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Pretreatment of T84 cells with Bafilomycin A1 reversed the anti-inflammatory effect 
mediated by HDL 
Bafilomycin is a selective inhibitor of vacuolar ATP-ase, it increases the pH of acidic 
vesicles and thereby prevent the fusion of autophagosomes with lysosomes, inhibiting the 
late stages of autophagy. We next tested if pretreatment of T84 cells with 100 nM 
Bafilomycin A1 had any effect in the anti-inflammatory effect mediated by HDL. As 
shown in Fig 26, preincubation of T84 cells with Bafilomycin A1 prior to HDL addition 
significantly decreased the ability of HDL to suppress TNF induced expression of TNF. 
 
 
Figure 26: Anti-inflammatory effect of HDL is decreased in the presence of autophagosome fusion 
inhibitor bafilomycin A1 
T84 cells were incubated with 100 nM bafilomycin A1 for 6 hours to inhibit autophagy, 
after which HDL was added for 18 hours prior to treatment with 25 ng/mL TNF for 3 
hours. mRNA expression of TNF was quantified relative to actin; n=3. 
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Uptake of gold labeled HDL into HT29 cells 
When colon carcinoma HT29 cells were incubated with gold labeled HDL for 18 hours, 
HDL was endocytosed in vesicles resembling autophagosomes with typical characteristics 
of engulfed cytoplasmic material and organelles (Fig 27). 
 
Figure 27: Uptake of gold labeled HDL into autophagosome 
HT29 cells were incuabated with 8nm gold labeled HDL for 18 hours, after which the cells were 
fixed and embedded in epon araldite for electron microscopy. 
The arrow represent gold labeled HDL. The organelle in close proximity to autophagosome could 
possibly be lysosomes. 
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Lipid droplet in vicinity of an autophagosome displaying a possibility of cholesterol exchange 
between autophagosome and lipid droplet. 
Intracellular transport and anitiinflammatory effect of HDL is mediated by tubulin  
Tubulin has been shown to mediate intracellular transport of HDL. Inorder to study the 
role of microtubules in the anti-inflammatory effect mediated by HDL, T84 cells were 
incubated with 5 µM colchicine which binds tubulin and block its polymerisation prior to 
HDL addition. As shown in Fig 28, colchicine significantly (n=3) decreased the ability of 
HDL to suppress TNF induced expression of TNF. With regard to the proposed autophagy 
mechanism, inhibition of tubulin might hinder efficient uptake of HDL by 
autophagosomes, there are also studies showing that autophagosomes might also exploit 
tubulin for their intracellular transport and fusion with lysosomes. 
 
Figure 28: Anti-inflammatory effect of HDL is dependent on tubulin 
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5 DISCUSSION 
5.1 Association of single nucleotide polymorphisms of FXR in IBD 
The complex pathophysiology of IBD still remains largely unelucidated, although multiple 
factors, both genetic and environmental, are clearly involved. SNPs and mutations within 
several genes have been proposed to be associated with the risk to develop IBD.  
In this report, we describe the identification of single nucleotide polymorphisms associated 
with the diagnosis of IBD within the NR1H4 gene, encoding the nuclear receptor for bile 
acids, FXR, in a well-sized European cohort. Five NR1H4 SNPs were analyzed, all of 
which have previously been studied in the context of other human disease conditions: 
rs3863377, rs7138843, rs56163822, rs35724, and rs10860603. The NR1H4 variants 
rs7138843 and rs56163822 have been previously shown to be inversely associated with 
cholelithiasis in a Mexican population and may thus play a protective role in gallstone 
disease, while the variant rs3863377 showed no association with cholelithiasis [204]. The 
variant rs56163822 was found to be more common in a British control group than in 
patients with intrahepatic cholestasis of pregnancy (ICP), although this difference did not 
reach statistical significance [205]. NR1H4 variants rs35724 and rs10860603 have been 
previously shown to be significantly associated with elevated body mass index and obesity 
[206]. IBD is often associated with hepatobiliary manifestations [207, 208], implying that 
the etiology of the diseases affecting the two organs, intestine and liver, may have common 
factors, also supported by our findings that the same NR1H4 genetic variants may be 
associated with both. The variant rs3863377 is located in the 5’ region of the NR1H4 gene, 
whereas the rs7138843 lies within the NR1H4 intron 7 and variants rs35724 and 
rs10860603 within NR1H4 intron 9. In none of these cases is it known, how the presence 
of the SNP may affect the expression and/or molecular function of FXR. As the SNP 
rs3863377 is located within the 5’ region, it may alter a binding site for a transcription 
factor and may thus affect NR1H4 gene expression. The intronic SNPs rs7138843, 
rs10860603, and rs35724 could potentially influence splicing of the FXR mRNA. The 
substitution -1G>T in rs56163822 lies in the base position adjacent to the translation 
initiation site, and was shown to lead to reduced FXR protein expression and decreased 
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level of FXR-dependent promoter activation in human embryonic kidney cells. In another 
study the functional activity of the -1G>T variant also appeared to be compromised, 
although transcriptional and translational efficiencies of the variant appeared comparable 
to the wild-type in cell-free assays and in HeLa cells [209]. Interestingly, the mRNA 
expression levels of the FXR target genes SHP and OATP1B3 are significantly reduced in 
the livers of the carriers of the rs56163822 allele, while the FXR mRNA expression level 
remains comparable, further indicating that this polymorphism may rather lead to 
weakened function than to reduced expression level of FXR. 
In our current genotyping analysis we have found that for the NR1H4 variant rs3863377, 
the IBD population has a significantly lower frequency of carriers of the rarer allele than 
the healthy population, suggesting that this 5’ region SNP may confer a protective effect 
against the disease. In the case of the rs56163822 NR1H4 variant, the rare allele is 
significantly more prevalent in the IBD population, suggesting that previously reported 
reduced FXR function exhibited by this variant may contribute to IBD pathogenesis. In the 
case of the rare NR1H4 variant under study, rs7138843, and the common SNPs 
rs10860603 and rs35724, no significant differences between the study populations were 
observed. In agreement with the associations observed for two of the five single SNP 
variants, the predicted global haplotype pattern was significantly different in IBD patients 
and non-IBD controls. 
 In our study, five NR1H4 SNPs were investigated. During the preparation of our 
manuscript, Nijmeijer et al [210] published a study showing that mRNA expression of 
FXR and its target gene SHP are decreased in the ileum of Crohn’s disease patients, in 
further support of the importance of the role for FXR in IBD. These authors also studied 
potential association of nine NR1H4 SNPs with IBD in a Dutch population, but did not 
discover any associations that remained significant upon correction for multiple testing. 
We note that in their analysis Nijmeijer et al did not include the SNP rs3863377, the 
inverse association by which with IBD remained significant even after Bonferroni 
correction in the current study. As numerous further polymorphisms are known to exist in 
the NR1H4 gene (www.ncbi.nlm.nih.gov/snp/), our report, as well as that by Nijmeijer et 
al, serve as initial characterizations of the role of FXR genetic variants in IBD. 
Furthermore, these findings warrant further studies into genetic variants in the NR1H4 
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gene in the context of other inflammatory conditions affecting further tissues that express 
FXR. FXR ligands, such as the hydrophilic bile acid ursodeoxycholic acid, have been 
proposed as attractive options for the therapy of liver diseases, such as cholestatic disease 
and non-alcoholic fatty liver disease [211]. Our finding that FXR genetic variants are 
associated with IBD, together with prior observations on FXR expression being altered in 
Crohn’s disease [210] and on FXR promoting intestinal barrier integrity [27] and 
antibacterial defence [26], further emphasizes the potential benefits of FXR ligand 
administration also in IBD. We further speculate that testing for genetic variation in the 
NR1H4 gene may contribute to the early IBD diagnosis and prediction of therapy response 
in the future. 
 
5.2 HDL and its major protein ApoA1 suppress intestinal inflammation 
IBD patients of both genders display dyslipidemia with significantly lower HDL-
cholesterol (C). Since HDL is a negative acute phase reactant and since the intestine is the 
second most important site of HDL production, the low HDL cholesterol has traditionally 
been interpreted to be the consequence of IBD. Since HDL exerts many anti-inflammatory 
activities on many cells including endothelial cells, pancreatic beta cells and leukocytes, 
we hypothesized that HDL may also modulate intestinal inflammation [7, 212-215]. Both 
in vitro and in vivo we found evidence for anti-inflammatory effects of HDL and ApoA1 in 
the intestine.  
The pro-inflammatory cytokine TNF is a key mediatior of mucosal inflammation in both 
Crohn’s disease (CD) and ulcerative colitis (UC) and alters the integrity of epithelial and 
endothelial cell barriers [216, 217]. Increased concentrations of TNF have been found in 
blood, mucosa and faeces of CD patients. In several animal models of IBD, genetic 
ablation or anti-TNF treatment result in amelioration of mucosal inflammation. 
Furthermore, infliximab, a monoclonal antibody against TNF  has been effective in clinical 
management of IBD [92, 150, 218, 219].  We therefore used TNF as a pro-inflammatory 
stimulator for our in vitro experiments. Preincubation of coloncarcinoma T84 cells with 
HDL or ApoA1 for 18 hrs significantly suppressed TNF triggered mRNA expression of 
IL-8, ICAM and TNF by inhibiting NF-κB promoter activity as measured by relative 
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luciferase activity and NF-κB DNA binding activity by EMSA. These findings are very 
similar to those previously made in experiments with endothelial cells and vascular smooth 
muscle cells where HDL was also found to reduce cytokine production and adhesion 
molecule expression via inhibition of NF-κB [143, 220, 221]. 
Importantly the anti-inflammatory properties of HDL and ApoA1 could be reproduced in 
an animal model of colitis. Upon DSS-treatment, ApoA1 KO phenotype exhibited a more 
severe intestinal inflammation as compared to WT mice as indicated by increased mucosal 
damage upon both colonoscopy and histology, shorter colon length, as well as increased 
intestinal MPO activity and mRNA expression of TNF and ICAM. Conversely, ApoA1 Tg 
mice, which have elevated levels of HDL, were partially protected from DSS induced 
mucosal damage as indicated by less severe symptoms upon colonoscopy and less severe 
increases in MPO activity. The functional importance of the attenuated intestinal 
inflammation in ApoA1 Tg mice is highlighted by the fact that WT mice and ApoA1 KO 
mice but not ApoA1 Tg mice, lost body weight upon DSS treatment. These observations 
are in very good agreement with previous findings of Cuzzocrea and colleagues who 
showed that administration of reconstituted HDL reduces intestinal inflammation in 
animals with splanchnic artery occlusion shock or dinitrobenzene sulfonic acid (DNBS)-
induced colitis [222].  
HDL and ApoA1 have been increasingly recognized as a part of innate immune system for 
their ability to bind and neutralize the toxic effects of lipopolysaccharide (LPS), a bacterial 
product that can activate Toll-like receptors stimulating the secretion of cytokines [223]. 
This function may be of special importance in the control of barrier integrity, for example 
in the vascular endothelium and the intestinal epithelium.  
5.3 Anti-inflammatory effect of HDL and ApoA1 is mediated via 
activation of autophagic pathway  
In this study, we report that HDL and ApoA1 induce autophagy in T84 cells. We provide 
evidence that anti-inflammatory effects exerted by HDL on T84 cells could be mediated 
via activation of autophagy. We also show that inhibition of autophagy reverse the anti-
inflammatory effect exerted by HDL on T84 cells. Increase in LC3-II is an indicator of 
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pre-autophagosome formation. In our experiments, we observed increased processing of 
LC3 in the presence of HDL and ApoA1. This correlated with a decrease in 
phosphorylation of mTOR, a negative regulator of autophagy. Chemical inhibition of 
autophagic pathway using Wortmannin and 3-Methyl adenine decreased the ability of 
HDL to decrease TNF induced NF- κB responsive promoter activity as well as  expression 
of TNF mRNA expression. Interestingly pretreatment of T84 cells with Bafilomycin A1 
which inhibits the late stages of autophagosome fusion to lysosomes also inhibited the 
suppressive effect mediated by HDL on TNF induced mRNA expression of TNF. The 
intracellular transport of HDL seems to be tubulin mediated as demonstrated by the reverse 
effect of HDL when T84 cells were incubated with Colchicine, a tubulin blocker. 
Where as SiRNA knockdown of LC3 significantly decreased the ability of HDL to 
suppress inflammation, SiRNA knock down of HDL receptors SRB1 and ABCA1 did not 
have any effect (data not shown). This observation co-ordinated well with our studies in 
human fibroblasts harboring ATG16L1 mutation. Further, we observed uptake of gold 
labeled HDL in autophagosomes which clearly depicted engulfed organelles such as 
mitochondria and these were found in close proximity to lipid droplets. 
These results give an initial indication that autophagy might regulate inflammatory 
pathways in intestinal cells and HDL might modulate inflammation via autophagy. Genetic 
variation and dysfunction in autophagy genes IRGM and ATG16L1 has been implicated in 
improper bacterial handling and abnormalities in Paneth cells [160]. Recently Scharl et.al 
published an interesting study showing that PTPN2 maintain intestinal barrier functions 
and limits the effects of proinflammatory cytokines by up-regulating autophagy [224]. This 
study also shows that expression of autophagy proteins ATG16L1, IRGM, LC3 and 
ATG5-ATG12 are significantly decreased in inflamed mucosa of CD patients. In human 
endothelial cells, HDL has been shown to inhibit Oxidised LDL induced ER stress and 
autophagy [225]. Our study therefore depicts a tissue specific function of HDL, taking into 
account that intestine plays a major role besides liver in HDL/ApoA1 synthesis and 
metabolism and the high antigenic exposure in intestine bring together, a relevant role of 
HDL in maintaining barrier integrity of intestine by modulating autophagy. Possibly HDL 
recruit specific substrates such as phosphorylated IKK for autophagy mediated degradation 
there by suppressing inflammation.  
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CONCLUSIONS/ FUTURE PERSPECTIVES 
In conclusion, the results of first project support the role for FXR as a modulator of 
intestinal inflammation and as an important player in enteroprotection. The link between 
the bile acid receptor FXR and IBD also further emphasizes the potential importance of 
bile acid homeostasis and metabolism in the pathogenesis of IBD. The experiments 
presented in project 2 demonstrate the capability of HDL and ApoA1 in protecting 
intestinal cells against inflammation induced damage. We show that HDL and ApoA1 
suppress intestinal inflammation by attenuating NF-κB signalling. Present day therapy of 
IBD consists of salicylates, corticosteroids and immunosuppressants, most of which cause 
severe side effects. Modulation of HDL or ApoA1 serum levels may be an attractive 
approach to treat the chronic inflammatory reaction in IBD patients. In the third project, we 
provide evidence that HDL might modulate autophagy and thereby mediate suppression of 
intestinal inflammation. However there are several limitations to the present study. Despite 
the progress outlined above, there remain important questions that require further study in 
relation to a more complete understanding of mechanisms by which FXR, HDL and 
ApoA1 modulate inflammation. These include: 
 Functional analysis of FXR variants, rs3863377 and rs56163822 which associated 
with IBD, could give more insight into how exactly the variants influence FXR gene 
expression and function and its significance to IBD.  
 The in vivo data demonstrating anti-inflammatory effect of ApoA1 was done in an 
acute DSS colitis model. It is important to reproduce these result in a chronic model of 
DSS colitis which resemble the chronic phase of UC and CD and enable us to 
elucidate the significance of ApoA1 in chronic inflammation. 
 It is also important to put some thoughts into the mechanisms upstream of autophagy 
which HDL might modulate. Presently we demonstrate that HDL is take up by the 
process of autophagy and induce genes relevant for autophagy. We also show that lack 
of autophagy genes decreases the anti-inflammatory effect of HDL, but how exactly 
HDL induced autophagy suppresses inflammation is still a question to resolve.  
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